Pharma Report on Epstein-Barr Virus (HHV-4) Infections – Pipeline Review, H2 2020

Source: https://www.researchbymarkets.com/report/epstein-barr-virus-hhv-4-infections-pipeline-review-h2-2020-645803.html

Epstein-Barr Virus (HHV-4) Infections – Pipeline Review, H2 2020

Summary

Epstein-Barr Virus (HHV-4) Infections – Pipeline Review, H2 2020, provides an overview of the Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline landscape.

Epstein-Barr virus (EBV) or human herpes virus 4 virus is a member of the Herpesviridae family. It is one of the most common human viruses to cause cancer in humans and is associated with a wide range of human cancers originating from epithelial cells, lymphocytes and mesenchymal cells. It spreads most commonly through bodily fluids. It can also spread through blood and semen during sexual contact, blood transfusions, and organ transplantations. Symptoms of EBV infections include fatigue, fever, and inflamed throat, swollen lymph nodes in the neck, enlarged spleen, swollen liver and rash. Treatment includes over-the-counter pain and fever medications to get relief from the symptoms of the disease.

Report Highlights

Epstein-Barr Virus (HHV-4) Infections – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Epstein-Barr Virus (HHV-4) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 8, 3, 8, 5 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 9, 4, 6 and 4 molecules, respectively.

Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Epstein-Barr Virus (HHV-4) Infections (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
Advenchen Laboratories LLC
AlloVir Inc
Atara Biotherapeutics Inc
Boryung ViGenCell Inc
Bristol-Myers Squibb Co
Children’s National Research Institute
China Immunotech Co Ltd
Cullinan Oncology LLC
Eutilex Co Ltd
Galenbio Ltd
Geneius Biotechnology Inc
Genocea Biosciences Inc
Good T Cells Inc
Immunotech Biopharm Ltd
Incyte Corp
Karyopharm Therapeutics Inc
Lion TCR Pte Ltd
Moderna Inc
Omeros Corp
Oxford Vacmedix UK Ltd
Replicate Bioscience Inc
Savoy Pharmaceuticals Inc
Viracta Therapeutics Inc
Vironika LLC
ViroStatics SRL


For queries regarding this report: https://www.researchbymarkets.com/sample-request/645803

Contact Us:
ResearchByMarkets.com
Ritesh Tiwari, Director
enquiry@researchbymarkets.com
USA: +1-800-416-3124
https://www.researchbymarkets.com
https://www.researchbymarkets.com/aboutus

Follow us on Social Media:
Facebook: https://www.facebook.com/researchbymarkets/
LinkedIn: https://www.linkedin.com/company/researchmarkets
Twitter: https://twitter.com/ResearchByMrkts

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: enquiry@researchbymarkets.com *Industry Press Release is a part of Research By Markets.